News | January 18, 2012

Baptist Cardiac and Vascular Institute Aligns With Top European University to Access Latest Device Technology

The University of Heidelburg

The University of Heidelburg

January 18, 2012 — Baptist Cardiac & Vascular Institute of Miami announced a partnership with the University of Heidelberg, one of the largest and most important centers for patient care, medical research and teaching in Europe, for hands-on access to the latest medical innovations.

"Our institute has set the agenda in South Florida for cardiac and vascular procedures and treatment, but a lot of medical innovations are happening outside the United States. Our affiliation with the University of Heidelberg will bring a new line of knowledge in clinical medicine and broaden our perspective about new developments in patient care," Barry T. Katzen, M.D., founder and medical director of the institute, said.

The relationship will benefit South Florida patients, granting access to the most advanced treatments available for cardiac and vascular systems performed by heart surgeons, interventional radiologists and vascular surgeons.

"In our regulatory environment, it takes three to four years for innovations to be approved here. Our doctors, by traveling to Heidelberg, will already have been involved in early-stage technology. Over time it will have significant implications in patient care," Katzen said.

Dittmar Bockler, M.D., medical director and chairman of the department for vascular and endovascular surgery at Heidelberg University Hospital, agrees the partnership will result in better care for patients in the United States and Germany.

"Whenever there is transatlantic collaboration, the shared knowledge results in new developments and refinements," Dr. Bockler said. "Baptist Cardiac & Vascular Institute is a leader in multidisciplinary care and has pioneered many procedures that are of great interest to European physicians."

Both organizations are renowned as groundbreakers in cardiovascular care, involved in dozens of clinical trials and sophisticated diagnostic, treatment and rehabilitation services. They share a goal of searching for the least invasive treatments, particularly important for an aging population. Teams of interventional radiologists, clinical and interventional cardiologists, cardiothoracic surgeons, vascular surgeons, electrophysiologists, and neuroradiologists work together to provide a spectrum of care ranging from wellness to the most complex endovascular and open surgical procedures for heart and circulatory problems.

Baptist Cardiac & Vascular Institute, established in 1987, is part of Baptist Health South Florida, the largest faith-based, not-for-profit healthcare organization in the region.

For more information: www.baptistheart.net

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init